TemanogrelA drug candidate for the prevention and treatment of coronary microvascular obstruction. Temanogrel is an investigational, peripherally acting, and selective 5-HT2A receptor inverse agonist designed to inhibit serotonin (5-HT)-mediated amplification of platelet aggregation and vasoconstriction. Temanogrel will be entering Phase 2 for coronary microvascular obstruction, or cMVO, in H1 2021.
Clinical TrialTemanogrel is an investigational drug and is not currently approved for use by any health authority.
CORONARY MICROVASCULAR OBSTRUCTION